Table 1.
Variable | Upper GI CD (n = 24) | Other site CD (n = 787) | P-value |
---|---|---|---|
Age at diagnosis (yr) | 27 ± 12 | 26 ± 10 | 0.75 |
Age at operation (yr) | 33 ± 11 | 32 ± 10 | 0.61 |
Sex, female : male | 3 (12.5) : 21 (87.5) | 233 (29.6) : 554 (70.4) | 0.07 |
Duration of disease (mo) | 73.6 ± 56.6 | 69.7 ± 61.1 | 0.87 |
Follow-up duration (mo) | 147.1 ± 59.7 | 145.1 ± 69.5 | 0.88 |
Body mass index at operation (kg/m2) | 17.76 ± 2.27 | 18.55 ± 3.10 | 0.11 |
Hospital stay (day) | 36.6 ± 58.4 | 19.4 ± 16.6 | 0.001* |
Family history of CD, yes | 0 (0) | 24 (3.0) | 0.48 |
History of smoking | 0.035* | ||
None | 10 (41.7) | 521 (66.2) | |
Ex-smoker | 11 (45.8) | 191 (24.3) | |
Current smoker | 3 (12.5) | 75 (9.5) | |
Previous abdominal surgery, yes | 11 (45.8) | 266 (33.7) | 0.45 |
Previous perianal surgery, yes | 15 (62.5) | 319 (40.6) | 0.036* |
History of fistula-in-ano | 0.06 | ||
Yes | 17 (70.8) | 393 (49.9) | |
No | 7 (29.2) | 394 (50.1) | |
Montreal classification behavior | 0.76 | ||
Nonstricturing, nonpenetrating (B1) | 2 (8.3) | 42 (5.4) | |
Stricturing (B2) | 10 (41.7) | 270 (34.3) | |
Penetrating (B3) | 12 (50.0) | 475 (60.3) | |
Montreal classification location | 0.015* | ||
Ileocolic (L1) | 4 (16.7)a | 346 (43.9) | |
Colic (L2) | 4 (16.7)a | 54 (6.9) | |
Ileal (L3) | 16 (66.7)a | 387 (49.2) | |
Medication | |||
5-Amino-salicylic acid or no medication | 8 (33.3) | 339 (43.1) | 0.21 |
IMM | 10 (41.7) | 243 (30.9) | 0.27 |
Anti-TNF-a | 1 (4.2) | 48 (6.1) | 0.57 |
Steroid | 0 (0) | 42 (5.3) | 0.63 |
IMM+TNF | 3 (12.5) | 54 (6.9) | 0.24 |
IMM+steroid | 2 (8.3) | 41 (5.2) | 0.37 |
Steroid+TNF | 0 (0) | 8 (1.0) | 0.79 |
All combination | 0 (0) | 12 (1.5) | 0.70 |
Values are presented as mean±standard deviation or number (%).
CD, Crohn disease; GI, gastrointestinal; IMM, immunomodulatory; TNF, tumor necrosis factor.
P<0.05, significant differences.
This number and proportion included other site Crohn disease with upper gastrointestinal Crohn disease.